수의용 원료의약품 제조 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 서비스 유형별, 합성 유형별, 동물 유형별, 치료 카테고리별, 지역별, 경쟁(2021-2031년)
Veterinary Active Pharmaceutical Ingredients Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Service Type, By Synthesis Type, By Animal Type, By Therapeutic Category, By Region & Competition, 2021-2031F
상품코드:1953693
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 수의용 원료의약품 제조 시장은 2025년 105억 6,000만 달러에서 2031년까지 162억 7,000만 달러로 대폭 확대하며, CAGR 7.47%로 성장할 것으로 예측됩니다.
이러한 원료의약품은 가축 및 반려동물을 위한 의약품 제조에 필수적인 약리학적 성분으로 작용합니다. 이러한 시장 성장의 기반은 고급 치료 솔루션을 필요로 하는 인수공통전염병의 발생률 증가와 고품질 동물성 단백질에 대한 전 세계 수요 증가에 기인합니다. 또한 반려동물을 가족의 일원으로 여기는 동향이 수의학 분야에 대한 막대한 투자를 촉진하고 있습니다. 미국 반려동물제품협회(APPA)에 따르면 2024년 미국 반려동물 산업의 총 지출은 약 1,520억 달러에 달할 것으로 예상되며, 이는 업스트림 제약 원료 수요를 촉진하는 탄탄한 재정적 기반을 제공합니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
105억 6,000만 달러
시장 규모 : 2031년
162억 7,000만 달러
CAGR : 2026-2031년
7.47%
가장 빠르게 성장하는 부문
반려동물
최대 시장
북미
그러나 시장은 다양한 국제 관할권의 엄격하고 다양한 규제 기준을 충족해야 하는 복잡성으로 인해 장벽에 직면해 있습니다. 제조업체는 유럽의약품청, FDA 등의 기관에서 시행하는 엄격한 승인 절차를 준수해야 하며, 이로 인해 컴플라이언스 비용 상승과 개발 기간의 장기화를 초래하고 있습니다. 이러한 단편적인 규제는 새로운 활성 성분의 상업적 도입을 지연시키고, 새로운 세계 시장으로 사업을 확장하고자 하는 제조업체에게 큰 장벽이 되고 있습니다.
시장 성장 촉진요인
세계 반려동물 사육률 증가와 동물의 인간화 추세가 주요 성장 동력이 되고 있으며, 업계의 초점은 단순한 질병 치료에서 첨단 건강 유지 및 예방 의료로 이동하고 있습니다. 반려동물을 가족의 일원으로 인식하는 경향이 강해지면서 골관절염, 피부병, 심장병 등 만성질환에 대한 전문적 치료에 대한 지불 의향이 높아지고 있습니다. 이러한 문화적 변화로 인해 장기적인 투약 계획을 지원할 수 있는 다양한 유효성분의 안정적인 공급망이 요구되고 있습니다. 2024년 5월 북미 반려동물 건강보험협회 데이터에 따르면 미국의 반려동물 보험 보험료는 39억 달러에 달하고, 고가의 치료에 대한 소비자 접근을 보장하고 제조 수요를 지속할 수 있는 재정적 기반을 마련하고 있습니다.
반려동물 분야와 더불어 동물성 식품 단백질에 대한 수요 증가는 축산 및 양식업의 생산 효율성 향상에 대한 필요성을 촉진하고 있습니다. 늘어나는 인구를 먹여 살리기 위해 생산자들은 고밀도 사육 환경에서 가축의 건강 유지와 질병 예방을 위해 동물용 의약품을 많이 사용하고 있으며, 항감염제 및 구충제의 필요량이 증가하고 있습니다. 미국 농무부 해외농업국은 2024년 4월 전 세계 닭고기 생산량이 사상 최대인 1억 330만 톤에 달할 것으로 예측하며, 의약품 지원이 필요한 엄청난 규모를 강조했습니다. 또한 Zoetis는 2024년 2023 회계연도 매출이 85억 달러에 달할 것으로 예상하고 있으며, 이는 API 제조업체가 필수 의약품의 지속적인 공급을 보장하기 위해 대응해야 할 시장 규모를 반영하고 있습니다.
시장이 해결해야 할 과제
동물용 원료의약품 제조 시장의 가장 큰 제약은 세계 각국의 규제 기준이 다르기 때문에 달할 준수하기 어렵다는 점입니다. 제조업체는 유럽의약품청(EMA), FDA 등 각 기관이 규정한 서로 다르고 종종 상충되는 승인 프로토콜에 대응해야 합니다. 이러한 규제의 단편화로 인해 안전 시험과 행정 서류의 중복 작성, 운영 비용이 크게 상승하고 설비 확장 및 공정 최적화에 투입되어야 할 자본이 전용되는 경우가 많습니다.
그 결과, 새로운 원료의 상업화에 소요되는 시간이 길어지고, 제조업체는 신흥 시장의 요구에 신속하게 대응할 수 없게 됩니다. 이러한 장기화는 특히 충분한 재정적 여유가 없는 중소기업의 진입장벽을 높이고 있습니다. HealthforAnimals의 2023년 보고서에 따르면 새로운 동물용 의약품을 시장에 출시하는 과정에는 평균 1억 달러의 투자가 필요하며, 최대 10년이 소요된다고 합니다. 이러한 장기화되는 개발 일정은 활성 성분 제조업체의 매출 창출 단계를 지연시켜 전체 시장의 모멘텀을 저해하고, 업계가 새로운 치료 옵션을 얻는 속도를 늦추고 있습니다.
시장 동향
업계는 전통적 화학 합성에서 복잡한 생물학적 공정으로 초점을 옮겨 바이오의약품 및 단일 클론 항체 생산으로 전환하고 있습니다. 제조업체들은 반려동물에게 더 높은 특이성과 적은 부작용을 제공하는 고분자 치료제를 생산하기 위해 바이오리액터, 콜드체인 물류 등 전문 인프라에 대한 투자를 늘리고 있습니다. 이러한 전환은 피부염, 골관절염과 같은 만성질환에 대한 생물제제의 상업적 성공에 의해 촉진되고 있습니다. 예를 들어 Zoetis는 2025년 11월 조지아주 더글러스빌의 새로운 시설에 5억 9,000만 달러의 투자를 발표하여 단클론 항체 및 백신 생산 능력을 확대할 것이라고 발표하며, 이러한 진화에 필요한 막대한 자본 투입을 강조했습니다.
동시에, 동물용의약품 기업은 현대적 원료의약품 생산에 따른 높은 운영비용과 기술적 복잡성을 줄이기 위해 위탁개발생산기관(CDMO)에 아웃소싱을 가속화하는 추세입니다. CDMO를 활용하면 제약사들은 광범위한 사내 시설을 유지해야 하는 부담 없이 첨단 기술과 확장 가능한 생산 능력을 활용할 수 있으며, 신약개발에 자원을 집중할 수 있습니다. 이러한 외부 파트너에 대한 의존은 공급업체 간의 통합을 촉진하고 있습니다. 예를 들어 SeQuent Scientific은 2025년 11월 Viyash Lifesciences와의 합병 승인을 받아 반기 매출 164억 6,200만 루피의 통합 기업을 설립하여 국제 고객 증가하는 아웃소싱 수요에 대응할 수 있게 되었습니다.
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 수의용 원료의약품 제조 시장 전망
제6장 북미의 수의용 원료의약품 제조 시장 전망
제7장 유럽의 수의용 원료의약품 제조 시장 전망
제8장 아시아태평양의 수의용 원료의약품 제조 시장 전망
제9장 중동 및 아프리카의 수의용 원료의약품 제조 시장 전망
제10장 남미의 수의용 원료의약품 제조 시장 전망
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 수의용 원료의약품 제조 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
제15장 경쟁 구도
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market is projected to expand significantly, growing from USD 10.56 billion in 2025 to USD 16.27 billion by 2031, representing a CAGR of 7.47%. These active pharmaceutical ingredients serve as the essential pharmacological components utilized in creating medications for both livestock and companion animals. This market growth is fundamentally underpinned by the rising incidence of zoonotic diseases, which demands sophisticated therapeutic solutions, as well as the increasing global requirement for high-quality animal protein. Furthermore, the trend of treating pets as family members has spurred substantial investment in veterinary healthcare; according to the American Pet Products Association, total U.S. pet industry spending reached nearly USD 152 billion in 2024, providing a solid financial base that fuels the demand for upstream pharmaceutical ingredients.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 10.56 Billion
Market Size 2031
USD 16.27 Billion
CAGR 2026-2031
7.47%
Fastest Growing Segment
Companion Animals
Largest Market
North America
However, the market faces obstacles due to the complexity of meeting strict and varying regulatory standards across different international jurisdictions. Manufacturers must navigate demanding approval procedures enforced by bodies such as the European Medicines Agency and the FDA, leading to elevated compliance costs and prolonged development timelines. This regulatory fragmentation can delay the commercial introduction of new active ingredients and creates significant barriers for manufacturers aiming to extend their operations into new global markets.
Market Driver
The rising global trend of pet ownership and animal humanization serves as a major growth engine, shifting the industry's focus from simple disease treatment to advanced wellness and preventive care. Owners increasingly view their pets as integral family members, showing a greater willingness to pay for specialized therapies for chronic issues such as osteoarthritis, dermatology, and cardiology. This cultural shift necessitates reliable supply chains for diverse active ingredients to support long-term medication regimens. Data from the North American Pet Health Insurance Association in May 2024 indicated that U.S. pet insurance premiums hit USD 3.9 billion, establishing a financial trajectory that ensures consumer access to expensive treatments and sustains manufacturing demand.
Parallel to the companion animal sector, the escalating demand for animal-derived food proteins drives the need for enhanced production efficiencies in livestock and aquaculture. To feed a growing population, producers rely heavily on veterinary pharmaceuticals to maintain herd health and prevent disease in high-density farming environments, thereby increasing the volume of anti-infectives and parasiticides required. The USDA Foreign Agricultural Service forecast in April 2024 that global chicken meat production would reach a record 103.3 million tons, highlighting the massive scale requiring pharmaceutical support. Furthermore, Zoetis reported fiscal year 2023 revenue of USD 8.5 billion in 2024, reflecting the substantial market value that API manufacturers must service to ensure the continuous availability of essential medicines.
Market Challenge
A significant restraint on the veterinary active pharmaceutical ingredients manufacturing market is the difficulty of complying with divergent regulatory standards across global jurisdictions. Manufacturers are compelled to navigate distinct and often conflicting approval protocols set by agencies like the European Medicines Agency and the FDA. This regulatory fragmentation necessitates the duplication of safety studies and administrative documentation, which significantly raises operational costs and diverts capital away from facility expansion or process optimization.
Consequently, the time required to commercialize new ingredients is extended, preventing manufacturers from swiftly addressing emerging market needs. This lengthy duration creates high barriers to entry, particularly for smaller firms without deep financial reserves. According to HealthforAnimals in 2023, the process to bring a new veterinary medicine to market required an average investment of USD 100 million and spanned up to ten years. These prolonged development timelines delay the revenue generation phase for active ingredient producers, thereby hampering overall market momentum and reducing the speed at which new therapeutic options become available to the industry.
Market Trends
The industry is undergoing a shift toward biopharmaceutical and monoclonal antibody production, moving focus from traditional chemical synthesis to complex biological processes. Manufacturers are increasingly investing in specialized infrastructure, such as bioreactors and cold-chain logistics, to produce large-molecule therapeutics that offer higher specificity and fewer side effects for companion animals. This transition is driven by the commercial success of biologics for chronic conditions like dermatitis and osteoarthritis. For instance, Zoetis announced in November 2025 a USD 590 million investment in a new facility in Douglasville, Georgia, designed to expand capacity for monoclonal antibodies and vaccines, underscoring the massive capital commitment required for this evolution.
Simultaneously, there is a trend of accelerated outsourcing to Contract Development and Manufacturing Organizations (CDMOs) as animal health companies seek to mitigate the high operational costs and technical complexities associated with modern API production. By leveraging CDMOs, pharmaceutical firms can access advanced technologies and scalable production capacity without the burden of maintaining extensive internal facilities, allowing them to focus resources on drug discovery. This reliance on external partners is fostering consolidation among suppliers; for example, SeQuent Scientific received approval in November 2025 for a merger with Viyash Lifesciences, creating a combined entity with half-year revenues of INR 16,462 million to support the growing outsourcing needs of international clients.
Key Market Players
Zoetis Inc.
Alivira Animal Health Limited
Ofichem Group
Chempro Group
Siflon Group
Qilu Animal Health Products Co., Ltd.
Chemo Holding, S.L
SUAN FARMA S.A.U
MENADIONA
Excel Industries Ltd
Report Scope
In this report, the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service Type
In House
Contract Outsourcing
Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Type
Chemical-based API
Biological API
HPAPI
Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Animal Type
Production Animals
Companion Animals
Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Therapeutic Category
Antiparasitic
Anti-infectives
NSAIDs
Others
Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Region
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market.
Available Customizations:
Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Service Type (In House, Contract Outsourcing)
5.2.2. By Synthesis Type (Chemical-based API, Biological API, HPAPI)
5.2.3. By Animal Type (Production Animals, Companion Animals)
5.2.4. By Therapeutic Category (Antiparasitic, Anti-infectives, NSAIDs, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Service Type
6.2.2. By Synthesis Type
6.2.3. By Animal Type
6.2.4. By Therapeutic Category
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Service Type
6.3.1.2.2. By Synthesis Type
6.3.1.2.3. By Animal Type
6.3.1.2.4. By Therapeutic Category
6.3.2. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Service Type
6.3.2.2.2. By Synthesis Type
6.3.2.2.3. By Animal Type
6.3.2.2.4. By Therapeutic Category
6.3.3. Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Service Type
6.3.3.2.2. By Synthesis Type
6.3.3.2.3. By Animal Type
6.3.3.2.4. By Therapeutic Category
7. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Service Type
7.2.2. By Synthesis Type
7.2.3. By Animal Type
7.2.4. By Therapeutic Category
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Service Type
7.3.1.2.2. By Synthesis Type
7.3.1.2.3. By Animal Type
7.3.1.2.4. By Therapeutic Category
7.3.2. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Service Type
7.3.2.2.2. By Synthesis Type
7.3.2.2.3. By Animal Type
7.3.2.2.4. By Therapeutic Category
7.3.3. United Kingdom Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Service Type
7.3.3.2.2. By Synthesis Type
7.3.3.2.3. By Animal Type
7.3.3.2.4. By Therapeutic Category
7.3.4. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Service Type
7.3.4.2.2. By Synthesis Type
7.3.4.2.3. By Animal Type
7.3.4.2.4. By Therapeutic Category
7.3.5. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Service Type
7.3.5.2.2. By Synthesis Type
7.3.5.2.3. By Animal Type
7.3.5.2.4. By Therapeutic Category
8. Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Service Type
8.2.2. By Synthesis Type
8.2.3. By Animal Type
8.2.4. By Therapeutic Category
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Service Type
8.3.1.2.2. By Synthesis Type
8.3.1.2.3. By Animal Type
8.3.1.2.4. By Therapeutic Category
8.3.2. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Service Type
8.3.2.2.2. By Synthesis Type
8.3.2.2.3. By Animal Type
8.3.2.2.4. By Therapeutic Category
8.3.3. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Service Type
8.3.3.2.2. By Synthesis Type
8.3.3.2.3. By Animal Type
8.3.3.2.4. By Therapeutic Category
8.3.4. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Service Type
8.3.4.2.2. By Synthesis Type
8.3.4.2.3. By Animal Type
8.3.4.2.4. By Therapeutic Category
8.3.5. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Service Type
8.3.5.2.2. By Synthesis Type
8.3.5.2.3. By Animal Type
8.3.5.2.4. By Therapeutic Category
9. Middle East & Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Service Type
9.2.2. By Synthesis Type
9.2.3. By Animal Type
9.2.4. By Therapeutic Category
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Service Type
9.3.1.2.2. By Synthesis Type
9.3.1.2.3. By Animal Type
9.3.1.2.4. By Therapeutic Category
9.3.2. UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Service Type
9.3.2.2.2. By Synthesis Type
9.3.2.2.3. By Animal Type
9.3.2.2.4. By Therapeutic Category
9.3.3. South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Service Type
9.3.3.2.2. By Synthesis Type
9.3.3.2.3. By Animal Type
9.3.3.2.4. By Therapeutic Category
10. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Service Type
10.2.2. By Synthesis Type
10.2.3. By Animal Type
10.2.4. By Therapeutic Category
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Service Type
10.3.1.2.2. By Synthesis Type
10.3.1.2.3. By Animal Type
10.3.1.2.4. By Therapeutic Category
10.3.2. Colombia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Service Type
10.3.2.2.2. By Synthesis Type
10.3.2.2.3. By Animal Type
10.3.2.2.4. By Therapeutic Category
10.3.3. Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Service Type
10.3.3.2.2. By Synthesis Type
10.3.3.2.3. By Animal Type
10.3.3.2.4. By Therapeutic Category
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market: SWOT Analysis
